Skip to content
BY-NC-ND 3.0 license Open Access Published by De Gruyter June 2, 2014

Isolation of New Cytotoxic Metabolites from Cleome droserifolia Growing in Egypt

  • Shahira M. Ezzat EMAIL logo and Amira Abdel Motaal

The sulforhodamine B (SRB) assay was used to assess the cytotoxicity of the aqueous (AqEx) and ethanolic (AlEx) extracts, respectively, of the aerial parts of Cleome droserifolia (Forssk.) Del. against two human cancer cell lines, breast (MCF7) and colon (HCT116) adenocarcinoma. AqEx exhibited higher cytotoxic activity, thus its four subfractions, namely n-hexane (HxFr), chloroform (ClFr), ethyl acetate (EtFr), and n-butanol (BuFr) fractions, were also tested. Purifi cation of the more active ClFr and EtFr yielded nine compounds. Six terpenoids, guai-7(11),8-diene (C1), 1-hydroxy-guai-3,10(14)-diene (C2), 18-hydroxydollabela- 8(17)-ene (C3), (24E)-stigmasta-5,8-dien-3β-ol (C4), teucladiol [1α,5β-guai-10(14)- ene-4β,6β-diol] (C5), and buchariol (4,10-epoxy-6α-hydroxyguaiane) (C6), were isolated from ClFr and three fl avonol glycosides, isorhamnetin-3-O-β-D-glucoside (F1), quercetin- 3`-methoxy-3-O-(4``-acetylrhamnoside)-7-O-α-rhamnoside (F2), and kaempferol-4`-methoxy- 3,7-O-dirhamnoside (F3), were isolated from EtFr. Compounds C3 and F2 are new in nature. The isolated compounds were identifi ed using various spectroscopic methods (UV, IR, 1H NMR,13C NMR, HMQC, HMBC, and COSY). Compounds C1, C3, F2, and F3 showed significant cytotoxic activities against the two tested cell lines comparable to those of the anticancer drug doxorubicin®. The new compound C3 was the most active as it had the lowest IC50 values, (1.9 ± 0.08) and (1.6 ± 0.09) μg/ml corresponding to 6.5 and 5.4 μM, against MCF7 and HCT116 cells, respectively

Received: 2011-8-15
Revised: 2012-1-13
Published Online: 2014-6-2
Published in Print: 2012-6-1

© 1946 – 2014: Verlag der Zeitschrift für Naturforschung

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Downloaded on 11.5.2024 from https://www.degruyter.com/document/doi/10.1515/znc-2012-5-605/html
Scroll to top button